SENSEI Health

Sensei Biotherapeutics is a clinical-stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients. The company leverages its proprietary platforms, including the ImmunoPhage platform, which utilizes bacteriophage to engage the immune system, and the TMAb platform for tumor-selective antibody biologics. Following its February 2026 acquisition of Faeth Therapeutics, Sensei's lead program is PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway currently in Phase 2 for endometrial cancer. The company is also advancing solnerstotug (SNS-101), a monoclonal antibody targeting the VISTA immune checkpoint, in Phase 1/2 trials for advanced solid tumors. Sensei aims to provide personalized yet off-the-shelf therapeutic cocktails to overcome immune resistance in the tumor microenvironment.